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Abstract
Recombination is a mechanism whereby positive sense single stranded RNA viruses exchange segments of genetic
information. Recent phylogenetic analyses of naturally occurring recombinant flaviviruses have raised concerns regarding
the potential for the emergence of virulent recombinants either post-vaccination or following co-infection with two distinct
wild-type viruses. To characterize the conditions and sequences that favor RNA arthropod-borne virus recombination we
constructed yellow fever virus (YFV) 17D recombinant crosses containing complementary deletions in the envelope protein
coding sequence. These constructs were designed to strongly favor recombination, and the detection conditions were
optimized to achieve high sensitivity recovery of putative recombinants. Full length recombinant YFV 17D virus was never
detected under any of the experimental conditions examined, despite achieving estimated YFV replicon co-infection levels
of ,2.4610
6 in BHK-21 (vertebrate) cells and ,1.05610
5 in C710 (arthropod) cells. Additionally YFV 17D superinfection
resistance was observed in vertebrate and arthropod cells harboring a primary infection with wild-type YFV Asibi strain.
Furthermore recombination potential was also evaluated using similarly designed chikungunya virus (CHIKV) replicons
towards validation of this strategy for recombination detection. Non-homologus recombination was observed for CHIKV
within the structural gene coding sequence resulting in an in-frame duplication of capsid and E3 gene. Based on these data,
it is concluded that even in the unlikely event of a high level acute co-infection of two distinct YFV genomes in an arthropod
or vertebrate host, the generation of viable flavivirus recombinants is extremely unlikely.
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Introduction
The family Flaviviridae contains three genera of viruses of
significant human and veterinary importance: Hepacivirus (Human
Hepatitis C virus), Pestivirus (bovine viral diarrhea virus (BVDV)
and classical swine fever virus), and Flavivirus. The flaviviruses,
genus Flavivirus can be further subdivided into those viruses which
are transmitted by tick (tick-borne flaviviruses), mosquitoes
(mosquito-borne flaviviruses), and those with no known vector
[1]. The mosquito-borne flaviviruses, for example yellow fever
virus (YFV), and the four dengue virus serotypes (DENV 1–4), are
responsible for millions of infections and thousands of deaths
annually [2–5].
The flavivirus genome is ,11–12 Kb, which is comprised of a
positive sense single stranded RNA molecule that contains a
59methylguanosine cap but no poly-adenosine tail. This genome
contains one open reading frame (ORF), encoding three structural
proteins; (capsid (C), premembrane (prM), and envelope (E)) and
seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5), flanked by 59 and 39 untranslated regions
(UTR). The flavivirus virion is ,50 nm in diameter and is
comprised of an electron dense nucleocapsid core surrounded by
an endoplasmic reticulum derived lipid bilayer [6–8]. Within this
lipid bilayer are embedded the mature membrane and E proteins.
The E protein has three distinct domains; a receptor binding
domain, a central linker domain, and a dimerization domain
which contains the membrane fusion loop [9–11]. The flavivirus
virion contains 180 E proteins associated as dimers that are
oriented parallel to the lipid bilayer in an icosaheldral symmetry
[12].
Certain viruses belonging to the family Flaviviridae, principally
non-arthropod-borne members, have long been known to be
competent to undergo recombination. The seminal observation of
Flaviviridae recombination involved detection, by Northern blot
analysis, of cellular ubiquitin sequences which had been
incorporated into the BVDV genome [13]. The subsequent
development of pathogenic mucosal disease was always charac-
terized by the simultaneous presence of two distinct BVDV
biotypes classified as cytopathic (cp) and non-cytopathic (ncp)
based on cell culture phenotype [14]. Sequence analysis of viral
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tion-driven sequence duplications, deletions, insertions and
rearrangements within ncp-variants. However, .99% sequence
identity was detected between matched cp and ncp variants when
the non-recombinant regions were compared [15–18]. Further-
more, molecular characterizations of isolates derived from animals
exhibiting post-vaccination mucosal disease suggest that recombi-
nation can occur between ncp-BVDV wt and cp-BVDV vaccines
in persistently infected animals [19,20].
Hepatitis C virus (HCV; genus Hepacivirus) is capable of
initiating a persistent hepatatropic infection in humans. The
seminal observation of HCV recombination involved the detection
of a 2k/1b recombinant (RF1_2k/1b) in human serum samples
collected in St. Petersburg, Russia [21]. This recombinant has
been repeatedly isolated from human serum samples across a wide
geographic range, including: Russia, Ireland, Estonia, and
Uzbekistan [22–25]. Sequence analysis of these related isolates
suggests that they are all derived from a common ancestor which
likely recombined 50–80 years ago and subsequently spread over a
large geographic range [25]. Furthermore, three other distinct
inter-typic recombinant viruses have been identified: a 2i/6p
Vietnamese isolate [26], a 2b/1b Philippine isolate [27]; a
2(unknown subtype)/5a French isolate [23] and there are reports
of intra-typic recombination [28–30].
Until recently, evidence of recombination within the members
of Flavivirus genus was based solely on phylogenetic sequence
analyses. Such studies suggested that recombinant intra-typic
DENV exist across all four serotypes [31–37]. Cross-over regions
appear to be localized to the 59 end of the genome (prM, E, and
NS1) [31–36]. One report identified recombination in the DENV
1 NS3 gene sequence [37]. Perhaps the most interesting aspect of
these analyses has been the identification of DENV genomes that
appear to be mosaics resulting from multiple homologous
recombinant events [31,33,35,36]. One report suggested that a
sequenced isolate of DENV 1 contains three recombinant regions
coincident with six homologous polymerase jumps [37]. Intra-
typic recombination has been reported for Japanese encephalitis
virus (JEV) and St. Louis encephalitis virus (SLEV) [36] with cross-
over sequences localized to the E gene coding sequence.
Additionally, a recent report by Pickett and Lefkowitz (2009) has
also identified a recombinant West Nile virus (WNV) sequence
with the cross-over occurring in the NS5 polymerase gene [38].
However it should be noted, that in none of these studies was
recombinant clonally isolated or characterized. Furtheremore,
naturally occurring recombinant mosquito-borne/tick-borne fla-
viviruses have never been recovered for characterization under
laboratory conditions. With the exception of a recent report by
Taucher et al., (2009) [39], all previous reports of flavivirus
recombination have involved analysis of sub-cloned PCR
generated amplicons and/or sequences deposited in databases.
As such these reports have met with skepticism due to a lack of
empirical to substantiate recombinant events and secondary
analyses which have suggested that some ‘‘recombinant’’ sequenc-
es may be artifacts of incorrectly annotated or assembled sequence
files [40–42]. Furthermore, if recombination has occurred for
some of these viruses such as SLEV no evidence exists to sugest
this has had any significant impact on the viral epidemiology or
ecology.
The changing global pattern of human activity, including
increased travel and encroachment into sylvatic habitat, coupled
with recent explosions in competent vector populations have
dramatically increased the global distributions of many of these
viruses. WNV and SLEV are now both widely distributed across
North America and share a transmission cycle involving Culex
mosquitoes and passerine birds. Furthermore, the rapid global
expansion of the DENV 1–4 [3] has lead to Aedes mosquito driven
co-circulation of all four serotypes coincident with YFV transmis-
sion in large areas of South America and Africa. As a consequence,
a number of flaviviruses with similar ecological niches now have
sympatric geographic regions of endemic/epidemic transmission,
dramatically increasing the potential for arthropod vectors and/or
vertebrate hosts to become co-infected with multiple viruses. The
use of live attenuated flavivirus vaccines, such as the YFV 17D
vaccine and 17D derived chimeric vaccines for example the
ChimeriVax
TM platform [43], to control disease in regions of
epidemic/endemic transmission has been postulated to represent a
risk for co-infection and potential recombination [33,34,44]. Since
the propensity of factors that might facilitate flavivirus-flavivirus
co-infection interactions continues to rise, investigations into the
potential for the generation of wild-type (wt)/wt and wt/vaccine
recombinants is important for our understanding, and ability to,
predict how these viruses are likely to evolve if introduced into
natural transmission cycles. Experiments described in this paper
were designed to evaluate the potential of YFV 17D to undergo
homologous or non-homologous recombination. However, as
flavivirus recombination potential, which appears to be very
inefficient and potentially virus specific, [39] has only just begun to
be elucidated under laboratory conditions we evaluated intra-
genic recombination using similarly designed CHIKV replicons.
Given our established expertise with CHIKV reverse genetics
systems [45–47], the known propensity for alphaviruses to
recombine [48–52], and the similar natural transmission cycle
(Aedes mosquito to human) CHIKV appeared to be an ideal system
to serve as a positive recombination control to comparatively
analyze and optimize the relative efficiencies of intra-genic RNA
arthropod-borne virus recombination.
Materials and Methods
Cells
Baby hamster kidney (BHK) cells were maintained in alpha-
minimal essential medium (aMEM; Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS; Invitrogen,
Carlsbad, CA), 100 U/mL penicillin 100 mg/mL streptomycin
(pen-strep), L-glutamine (L-glu; CellgroH Mediatech, Inc.) and
vitamins and maintained at 37uC with 5% CO2. African green
monkey kidney (Vero) cells were grown in minimum essential
medium (MEM; Invitrogen, Carlsbad, CA) with 2% bovine
growth serum (Hyclone, Logan, UT), pen-strep, non-essential
amino acids (Sigma-Aldrich, St. Louis, MO), and L-glu and
maintained at 37uC in the presence of 5% CO2. Aedes albopictus
(C6/36) cells were grown in Liebovitz L-15 media with 10% FBS,
10% tryptose phosphate broth (Sigma-Aldrich, St. Louis, MO),
pen-strep, and 1% L-glu and maintained at 28uC. Aedes albopictus
(C710) cells were grown in Dulbecco’s minimum essential medium
(Gibco, Carlsbad, CA) with 10% FBS, pen-strep, L-glu, and
maintained at 30uC in the presence of 5% CO2. Vero cells used
for electroporation were grown in MEM with 5% FBS and pen-
strep and maintained at 37uC.
Plasmid Constructs
Alphavirus plasmid constructs. All plasmid constructs or
infectious clones (IC) containing replicon, defective helper, and full
length viral genomes were generated using standard polymerase
chain reaction (PCR) based cloning methodologies [53]. To
evaluate intra-genic homotypic recombination of CHIKV, a
replicon/defective helper system was designed which contained
complementary frame shift deletions (DFS), separated by 967 nt of
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engineered into the CHIKV structural ORF were chosen based on
ease of cloning. A 39 DFS of nt 9079–9191 in the E2 sequence was
engineered into both the CHIKV-LR IC [45] and a CHIKV-LR-
59 Cherry fluorescent protein expressing IC (Higgs lab,
unpublished) to generate replicon genomes CHIKV-LR-39D-
Rep and CHIKV-LR-39D-Cherry-Rep respectively (Figure 1B).
Additionally, a complementary 59 DFS of nt 7910–8092 in the
capsid sequence was engineered into both the CHIKV-LR IC and
CHIKV-LR-59 GFP IC [45] in concert with a major deletion of
6,897 nt of the CHIKV nonstructural cassette to generate
defective helper genomes CHIKV-LR-59D-Help and CHIKV-
LR-59D-GFP-Help respectively. Plasmid maps, primer sequences,
and detailed cloning methodologies available from the authors
upon request.
Flavivirus plasmid constructs. All YFV 17D plasmid
constructs were generated, or derived from, the parental YFV
17D IC (pACNR/FLYF-17D; [54]). This construct was further
modified in a two step cloning process to generate p17D RBZ IC
which contained a silent mutation at nucleotide (nt) 495 to allow
for incorporation of a unique BspEI and a Hepatitis D rybozyme
sequence immediately downstream of the viral sequence. Two
distinct 17D deletion mutant virus variants designated 17D 59 DE
and 17D 39 DE respectively, were constructed to permit evaluation
of YFV intra-genic heterotypic recombination (Figure 1A). Each
of these mutants contained an in-frame deletion in the E protein
coding sequence. Briefly, a 59 deletion of nt 1109–1324 was
engineered into p17D RBZ IC to generate p17D-59-DE-Rep and
a complementary 39 deletion of nt 1984–2236 was also engineered
into p17D RBZ IC to generate p17D-39-DE-Rep resulting in the
generation of two complementary deletions separated by 636 nt of
homologous coding sequence. Additionally, the parental YFV
Asibi IC (pYFV-As IC) as described by [55] was also modified by
incorporation of this RBZ sequence to generate pYFV-As RBZ
IC.
A5 9 fluorescent protein reporter cassette was also fused within
the viral open reading frame of each of the aforementioned YFV
IC genomes, comprised of 25 amino acids (aa) of the YFV capsid
sequence followed by the sequences for the reporter and a foot-
and-mouth disease virus 2A protease immediately fused to a
human codon optimized full length YFV capsid, sequence as
previously described [56]. Insertion of reporter cassettes into
flavivirus genomes in this way facilitated efficient exogenous gene
expression in vitro and in vivo with increased stability as compared to
classic 39 insertions [56,57]. Reporter cassettes expressing either
enhanced green fluorescent protein (GFP) or Cherry fluorescent
protein (Cherry) were engineered into the YFV constructs
including p17D RBZ IC, pYFV-As RBZ IC, and p17D 59/39
DE replicons to generate plasmid constructs p17D-GFP-RBZ IC,
p17D-Cherry-RBZ IC, pYFV-As-GFP-RBZ, p17D-39-DE-GFP-
Rep and p17D-59-DE-Cherry-Rep. Additionally, a YFV 17D
packaging construct was constructed, to facilitate trans packaging
of envelope protein sequence deletion mutants, by replacing the
GFP coding sequence of a VEEV-GFP replicon, previously
described by [58], with the sequences for the YFV 17D structural
genes.
Generation, isolation, and characterization of clonal
recombinant genomes
The basic experimental design for the generation and cell
culture purification of full length recombinant genomes was as
follows. Viral RNAs were in vitro transcribed from linearized
plasmid genomes using the mMESSAGE mMACHINE Sp6 Kit
(Ambion, Applied Biosystems, Foster City, CA) followed by LiCl
precipitation in accordance with manufacturer protocols. Reaction
yield was then quantified using a SmartSpec Plus spectrophotom-
eter and known quantities of RNA were electroporated, either
individually (negative controls) or as mixtures of specific ratios
(recombinant crosses as ten-fold serial dilutions), into either BHK-
21 or C710 cells. For all recombination experiments, immediately
Figure 1. Schematic representation of flavivirus and alphavirus recombinant crosses. A) Yellow fever virus 17D deletion mutant replicon
recombinant cross, B) chikungunya virus deletion mutant replicon/defective helper recombinant cross.
doi:10.1371/journal.pone.0023247.g001
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appropriate maintenance media and 1/5 of the total electropo-
ration suspension (,2610
6 cells), with the addition of 1.0 mL of
sterile maintenance medium, plated in a single well of a six-well
plate and incubated at 37uCo r3 0 uC for 24 h (alphavirus
experiments) to 72 h (flavivirus experiments). At the time of
electroporation, infectious centers assays [45] were performed for
those constructs engineered to contain fluorescent protein
expression cassettes, to permit visual estimation of co-infection
levels within each experimental set. At 24 h or 72 h post-
electroporation, cell culture supernatant was removed and stored
at 280uC. Additionally, total cellular RNA was harvested using
TRIzolH Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol.
Clonal populations of recombinant genomes were isolated via
infection of 1610
7 Vero cells in suspension with 500 mLo f
electroporation supernatant samples, with agitation for 1 h at
room temperature. Following this incubation, cells were seeded
into 96-well plates (,3.5610
4 cells per well; 150 mL total volume
per well) and incubated for 72 h at 37uC at which time all wells
were examined visually. For CHIKV intra-genic recombinant
crosses, total medium from those wells identified as positive for
cytopathic effects (CPE) was harvested and stored at 280uC for
additional analysis. Due to the non-cytopathic nature of YFV 17D,
especially when inoculated at a low multiplicity of infection (moi),
at 72 h post-infection all medium was removed from primary
isolation plates and placed in correspondingly labeled 96-well
plates and stored at 280uC. Plates were then fixed with
acetone:PBS (3:1) and stained using an indirect immunofluores-
cence assay. Briefly, plates were rehydrated with 16PBS followed
by sequential 40 m incubations at 37uC with 1:500 concentration
of a YFV NS1 specific murine monoclonal antibody designated
86.3a [59] and a 1:500 concentration of a goat-anti mouse IgG
human absorbed secondary antibody (Alexa FluorH 488 Dye;
Invitrogen, Carlsbad, CA). All wells were visually examined for the
presence of YFV 17D infectious foci using an Olympus IX-50
epifluorescence microscope.
All clonal recombinant isolates were amplified by a single
passage in C6/36 cells and, following a 48 h incubation,
supernatants were harvested for each designated recombinant
stock and stored at 280uC until analyzed for the presence of
infectious virus by plaque assay. Additionally, RNA was extracted
from supernatant samples QIAampH Viral RNA Mini Kit
(Qiagen, Valencia, CA) and C6/36 (TRIzol Reagent) cells and
subjected to sequence and Northern blot analysis respectively.
Virus quantification. Infectious virus samples were titered
by plaque assay as follows. Briefly, Vero cells were seeded in well
plates at ,70% confluence and allowed to attach and grow for 4–
6 h, directly inoculated with ten-fold serial dilutions of viral
samples and following a 1 h incubation overlayed with an agarose
overlay (alphavirus samples) or semi-solid carboxy methyl-cellulose
overlay (flavivirus samples). Alphavirus plaque assay plates were
then incubated at 37uC for 48–72 h (depending on the specific
virus being assayed), fixed with 3.8% formaldehyde solution,
stained with crystal violet, and scored, whilst flavivirus samples
were fixed and stained as above. Titers were calculated as plaque
forming units (pfu)/mL. Infectious virus samples assayed by virus
titration were as previously described [60]. Briefly, ten-fold serial
dilutions of virus samples were performed in a 96-well plate format
and seeded with Vero cells. Titers were calculated as log10 tissue
culture infectious dose 50 (log10 TCID50) per mL.
Northern blot. The presence of full length recombinant viral
genomes cellular RNA was assessed by Northern blot using the
NorthernMaxH-Gly glyoxal-based system for Northern blots
(Ambion, Applied Biosystems, Foster City, CA) and BrightStarH-
Plus membrane (Ambion) in accordance with manufacturer
protocols. RNA bound membranes were then probed with a virus
specific biotinylated 40 nt oligonucleotide probe (CHIKV-59UTR
BioProbe; 59-CACGTACACAGGATCCATGATGGGTTATT-
AATCTC TTGCT) at a concentration of 1.5 pM overnight at
42uC. Mixtures of virus specific synthetic RNAs were generated by
mixing equimolar amounts of in vitro transcribed purified viral
RNAs derived from plasmids of varying lengths; i.e. full length
,12.0 Kb, replicon ,8.0 Kb, defective helpers ,2.0–5.0 Kb and
included as molecular size markers. All Northern blot membranes
were developed using the BrightStarH BioDetect
TM nonisotopic
detection kit (Ambion) in accordance with manufacturers protocols
and chemiluminescence was detected by exposing the treated
membrane to Kodak Biomax XAR film (Sigma-Aldrich, St. Louis,
MO).
Sequencing of putative recombinants. Two clonal isolates,
per recombination experiment, from the lowest dilution in which
recombination was detected (minimum level of co-infection) were
selected for sequence analysis of the putative junction/cross-over
region. Briefly, RNA was isolated from the recombinant stocks
using the QIAamp viral RNA extraction and cDNA generated
using the SuperScript III First-Strand Synthesis kit (Invitrogen,
Carlsbad, CA). cDNA was then PCR amplified and amplicons
cloned into pBluescript SK+ (Stratagene, La Jolla, CA). The
EcoRV site was chosen to facilitate efficient cloning of blunt end
fragments between the T7 and T3 promoter/primer binding sites
to facilitate ease of insert detection and sequencing. Sequencing
reactions were performed at the University of Texas Medical
Branch (UTMB) Protein Chemistry Core and sequence files were
edited and analyzed using the GeneRunner 3.05 software suite.
Results
Analysis of CHIKV intra-genic recombination
To validate that our strategy of using viral genomes containing
intra-ORF deletions was indeed capable of detecting intra-genic
recombination of positive sense single stranded RNA viruses, the
relative efficiency of CHIKV intra-genic recombination was
evaluated using a replicon/defective helper system that contains
complementary 59 and 39 deletions in the structural ORF (Fig. 1B).
RNA from pCHIK-LR-39D-Rep, containing a 112 nt FSD in E2,
was co-electroporated against ten-fold serial dilutions of RNA
from pCHIK-LR-59D-Help, which possesses a 182 nt FSD in
capsid. RNAs derived from pCHIK-LR-39D-Cherry-Rep and
pCHIK-LR-59D-GFP-Help were also co-electroporated in parallel
(10 mg per RNA species) to verify co-infection efficiency within this
experimental set, 1.2610
7/10 mg each RNA.
Recombination was observed to occur within the 967 nt of the
structural ORF under investigation to a minimum of ,10
5 co-
infections. Clonal isolates of intra-genic recombinant CHIKV
could be directly purified from co-electroporation dilutions 10
6
(n=3 isolates) and 10
5 (n=2 isolates). CHIKV intra-genic
recombinant isolates were competent for replication in both Vero
and C6/36 cells and reached average titers of 2.96610
7 pfu/mL
by 48 h post-infection in C6/36 cells, which are comparable to
titers observed post-infection with infectious clone derived wt
CHIKV. It is important to note that CHIK-LR-59D-Rep is only
112 nt smaller in size than the CHIK-LR wt virus, and so size shift
analysis as applied in Sindbis virus recombination experiments
[50,51] was not possible in our experiments to verify the presence
of virus specific intra-genic recombinant RNAs. However,
Northern blot analysis (CHIKV-59UTR BioProbe) of all CHIKV
intra-genic recombinants successfully identified virus specific
Recombination of Yellow Fever and Chikungunya
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48 h post infection with putative intra-genic recombinants
(Figure 2; Lanes 5, 6, 7, 9, and 10).
The putative cross-over sequence, and entire region between
the engineered 59/39 DFS, of two isolates from co-infection
dilution ,10
5 was sequenced to determine the resulting gene
topology. Recombination appeared to have occurred between the
two DFS mutations as expected, however, the nature of this
recombination was non-homologous and resulted in the genera-
tion of a stable in-frame duplication of structural gene coding
sequence (Figure 3). This duplication was comprised of the 59 34
amino acids (aa) (104 nt) of the CHIK-LR-59D-Rep E3 coding
sequence followed by the 39 20aa (61 nt) of the CHIK-LR-39D-
Help capsid sequence and the generation of a new hybrid leucine
codon (CTG) at the jump point. This topology likely resulted in
the retention of the capsid-E3 cleavage signal sequences allowing
for efficient removal of the duplicated partial proteins during
structural gene transcription and translation, thus allowing for the
efficient expression of full length functional C and E3. This
topology remained stable over five blind passages in Vero cells
with no evidence of sequence evolution or loss of duplicated
structural gene sequences.
In vitro analysis of YFV 17D and Asibi full length and
replicon growth kinetics
All YFV full length and replicon viruses had specific infectivity
values within a comparable range (9.0610
5–1.8610
6/mg RNA)
indicating that all molecular manipulations resulted in the
generation of stable infectious YFV RNAs capable of initiating
viral replication. All YFV variants were analyzed for their ability
to grow and produce infectious particles following electroporation
in BHK-21 or VEEV-YFV-17D-Help BHK-21 packaging cells
respectively. YFVs 17D and Asibi containing a 59 intra-ORF
reporter expression cassette were replication competent following
electroporation in BHK-21 cells. However, insertion of GFP or
Cherry into YFV 17D ORF in a 59 orientation resulted in a ,24 h
lag in replicative kinetics and an approximately ten fold decrease
in peak titers (Figure 4A). Furthermore, RT-PCR analysis of
Asibi GFP, using oligo-nucleotide primers which flanked the GFP
expression cassette, indicated that although initially replication-
competent in BHK-21 cells, this reporter cassette was relatively
unstable, with a near complete loss of exogenous sequence being
observed following a single passage in C6/36 cells (data not
shown).
Interestingly this trend did not hold for the YFV 17D 59 and 39
envelope deletion replicons. Parallel electroporation of 17D 59 DE
Cherry and 17D 39D GFP on BHK-21 and BHK-21 VEEV-YFV-
17D-Help cells confirmed that the engineered sequence deletions
resulted in the generation of suicide 17D genomes and that these
genomes were only capable of spreading when full length E was
provided in trans. For these replicons, similar growth kinetics and
peak titers were observed for 17D 59 DE regardless of the presence
or absence of the Cherry coding cassette, while 17D 39 DE
displayed slightly lower peak titers than its respective GFP
containing replicon (Figure 4B). Nevertheless, 17D deletion
mutant replicons were observed to have similar growth and
fluorescent protein expression kinetic profiles as compared to full
length constructs, reaching peak titers by two to three days post-
electroporation albeit to $100-fold lower peak titers.
Optimization for detection and analysis of YFV 17D
deletion mutant recombination
Previous analysis has repeatedly demonstrated that electropo-
ration of BHK-21 cells with full-length flavivirus/alphavirus RNAs
over a range of 10 mgt o1 0
26 mg results in ten-fold serial dilutions
of electroporation efficiency (number of BHK-21 cells successfully
transfected) when quantified using infectious centers assay (C.E.
McGee unpublished). Electroporation of known concentrations of
RNA into known numbers of BHK-21 cells could be correlated to
an expected number of primary infections. Furthermore, analysis
of viral recombination has suggested that the conditions for cell
culture purification of putative recombinants are highly virus
specific (C.E. McGee unpublished data). Experiments were
performed to determine the optimal passage protocol and lower
limit of detection of a full length YFV 17D against a saturated
background (,2610
6 cells 100% infected) of DE replicons. Briefly
ten-fold serial dilutions of purified YFV 17D Cherry RNA (range:
10
1–10
26 mg RNA) were co-electroporated in BHK-21 cells
against 10 mg each 17D 59 DE and 17D 39 DE. One-fifth of the
total volume of each electroporation (,2.0610
2 cells in 2.0 mL
total volume BHK-21 maintenance medium) was then plated in a
single well of a six-well plate. At 24, 48, 72, and 96 h post-
electroporation, total supernatant was harvested and replaced with
sterile medium. Five hundred microliters were then used to
Figure 2. Northern blot analysis of chikungunya virus (CHIKV) intra-genic recombinant isolates. Blot was hybridized with CHIKV-59UTR
BioProbe. Lane 1: CHIKV RNA ladder (size markers indicate CHIKV RNAs of full length genomic, replicon, full length structural gene helper, and capsid
only structural helper respectively), Lane 2: CHIKV-LR-39D-Replicon only electroporation, Lane 3: CHIKV-LR-59D-Helper only electroporation, Lanes 4
and 8: CHIKV-LR-39D-Replicon/ CHIKV-LR-59D-Helper co-electroporations, and Lanes 5, 6, 7, 9, and 10: clonal recombinant isolates.
doi:10.1371/journal.pone.0023247.g002
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grown in six-well plates. Vero and C6/36 plates were examined
daily for up to four dpi for signs of expanding Cherry foci
indicating recovery of full length 17D Cherry. Analyses of
detection sensitivity performed in this way indicated that Vero
cells were ,100-fold more sensitive than C6/36 cells for the
detection of 17D Cherry when titrated against a saturated
background of envelope deletion replicons (data not shown).
Furthermore, it was determined that optimal detection was
achieved at 72 h post-electroporation to a sensitivity of 10
23 mg
17D Cherry RNA input (equivalent to ,50 infectious units as
determined by infectious centers assay).
To determine if detection sensitivity could be further increased,
500 mL of electroporation supernatant samples from 17D Cherry
dilutions 10
23–10
25, from the 72 h post-electroporation time
point were used to infect 1.0610
7 Vero cells in suspension (as
described above) followed by plating in 96-well plates. Analysis in
this way increased the sensitivity of 17D Cherry detection to a
dilution of 10
24 mg 17D Cherry RNA (,5 infectious units) a level
of sensitivity equivalent to that previously reported for a similarly
designed ‘‘recombination trap’’ which successfully purified recom-
binant JEV [39]. Therefore, based on these analyses, it was
decided that all attempts to recover 17D recombinant virus would
involve co-electroporation of the recombinant cross (envelope
deletion replicons) followed by a 72 h incubation at the
appropriate growth temperature. Then recovery of recombinant
viruses would be attempted by direct infection of 1.0610
7 Vero
cells in suspension followed by plating in a 96-well format and
incubation at 37uC with 5% CO2 for 72 h. Plates were then fixed,
stained by IFA, and all wells visually examined for the presence of
YFV 17D infectious foci which would be suggestive of the presence
of a full length recombinant virus. 17D 59 DE and 17D 39 DE co-
electroporation recombinant crosses (10 mg per RNA species) were
performed in triplicate in both BHK-21 and C710 cells. 17D 59 DE
Cherry and 17D 39 DE GFP were also co-electroporated (10 mg
per species) to allow for estimation of co-infection efficiency.
Despite achieving estimated YFV replicon co-infection levels of
,2.4610
6 in BHK-21 cells and ,1.05610
5 in C710 cells, no
evidence of YFV 17D recombination was detected.
Analysis of YFV superinfection resistance in Vero and
C710 cells
The most important requirement for the generation of a
recombinant viral genome is spatial and temporal association of
the donor and acceptor templates to allow for polymerase template
switching. For that, a vertebrate or mosquito vector would have to
either be simultaneously infected by two viruses, or superinfected
with a second virus while harboring a primary infection, followed
Figure 3. Schematic representation of parental replicon/defective helper recombinant cross (CHIK-LR-39D-Replicon and CHIK-LR-
5D9-Helper) along with sequence topology analysis of the cross-over region and resulting recombinant topology of clonally
isolated recombinant genomes. Genes not necessarily shown to scale. aa-amino acid, E-envelope glycoprotein, ns-nonstructural, nt-nucleotide,
LR-LaReunion, and UTR-untranslated region, @LR location of sequence deletion.
doi:10.1371/journal.pone.0023247.g003
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tion, amplification, and subsequent selection to occur. Superin-
fection resistance studies were therefore performed to determine if
primary infection with YFV Asibi would influence the replication
of a secondary infection with YFV 17D. Primary infections were
performed by electroporating RNA derived from a GFP
expressing Asibi IC. (YFV-As RBZ GFP IC); this virus was
chosen because it allowed for visual estimation of the percentage of
cells positive for primary YFV infection, without requiring
fixation. At seven days post-electroporation ($95% of cells
positive for GFP expression) cells were superinfected with virus
derived from a 17D Cherry RBZ IC. This virus was chosen for
these studies because the expression of the mCherry fluorescent
protein would allow for easy distinction between 17D and Asibi
during virus titration. Superinfection growth curves were also
performed using Asibi GFP infected cells and an unrelated
Figure 4. Comparison of post-electroporation growth kinetics of yellow fever viruses (YFV) and deletion mutants in BHK-21 cells. A)
YFV 17D (& solid line), YFV 17D GFP (& dashed line), and YFV 17D Cherry (# solid line); B) YFV 17D 59 DE( m), YFV 17D 39 DE(N), YFV 17D 59DE
Cherry (D), and YFV 17D 39 DE GFP (#). Titers expressed as plaque forming units/mL.
doi:10.1371/journal.pone.0023247.g004
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to verify that any changes in 17D replication kinetics (if observed)
were due to the establishment of YFV specific superinfection
resistance and not a result of Asibi infection resulting in the
induction of a non-specific antiviral state. Additionally, control
(mock) electroporated Vero and C710 cells were also infected with
either 17D-Cherry or CHIK-LR-59-Cherry in parallel.
Average titers of 17D-Cherry harvested from Vero cells that
were also infected with Asibi-GFP were approximately 0.5–1.0
log10TCID50/mL lower than from corresponding mock electro-
porated Vero cells at all times post-superinfection (Figure 5A).
17D Cherry was not detected (limit of detection 1.06 log10T-
CID50/mL) in Asibi GFP infected C710 cells beyond 24 h post-
infection, with titers at this time point likely representing residual
viral inoculum. Average titers of 17D Cherry harvested from C710
cells harboring a primary Asibi GFP were significantly (p,0.05)
lower at two, three, and four dpi as compared to corresponding
time points harvested from mock electroporated C710 cells.
Interestingly, primary infection with Asibi, in C710 cells, appeared
to result in the generation of a cellular environment that was
completely refractory to superinfection with/replication of 17D
(Figure 5B). As expected, previous infection with Asibi-GFP had
no significant untoward effect on CHIK-LR-59-Cherry replication
in either cells line used (Figure 5C,D).
Discussion
To date, all studies on RNA virus recombination can be
categorized into two approaches: 1) comparative phylogenetic
analysis of naturally occurring recombinant sequences, or 2)
detection of recombinant progeny from experimental cell culture
systems using high multiplicities of infection. In both cases, the
recombinant genomes that have been observed have undergone
extensive in vivo/in vitro replication and selection prior to sequence
analysis. The nature of these RNA-dependent RNA polymerase
template switches were then assessed retrospectively so that
inferences could be made about the nature of the event which
gave rise to the recombinant progeny. The vast majority of the
evidence for mosquito-borne flavivirus recombination, generated
in this way, has suggested that either genetic exchange occurs via
homologous recombination or that these observed homologous
recombination events were the result of the constraint on the need
to reproduce an intact and unmodified ORF. Simply put, if the
genetic filter for genome viability requires homologous-like
recombination, that is all that will be detected in nature.
Homologous recombination of picornavirus oral polio vaccines
is a well documented etiology of vaccine associated paralytic
poliomyelitis [61–63]. It has been hypothesized that homologous
flavivirus vaccine/vaccine or vaccine/wt recombination should be
considered as a potentially significant impediment to the
development of flavivirus live attenuated vaccines [34,35,44].
Given that these picornaviruses and flaviviruses have similar
coding strategies involving a single stranded positive sense genome
comprised of a single ORF, and, that naturally occurring
recombination has been well documented for two genera of the
family Flaviviridae (Hepacivirus, and Pestivirus), it may seem logical
to assume that all viruses belonging to the genus Flavivirus might
have similar propensities to undergo recombination. However,
OPV intra-vaccine replication coincident with virus shedding has
been observed to persist for $60 days post-vaccination [64–66],
however post-immunization replication of YFV 17D does not
persist for more than a few days and has been difficult to detect
even during severe adverse events [67]. Furthermore, it has been
noted that those strains of OPV that replicate longer in the host
have a higher propensity for recombination [66]. Since it is logical
to assume that recombination potential would be directly related
to replication persistence, and OPV and YFV 17D display
significant differences with regard to the duration of post-
vaccination replication, direct extrapolation of the conditions that
favor picornavirus recombination and its consequences with
respect to flavivirus vaccine safety is an overly simplistic view.
However, arthropod-borne flaviviruses have long been known
to cause persistent life long infections in arthropod vectors thus
allowing for multiple transmission events to occur. Although
vertebrate infection with these viruses is generally considered to be
acute, several studies have demonstrated the potential for
flaviviruses (genus Flavivirus) to establish persistent infection in
vertebrates. This should perhaps not be that surprising considering
the natural life-cycle of the hepaciviruses and pestiviruses involves
persistent infections in humans and agricultural animals, respec-
tively. Persistence has been documented for a number of
flaviviruses including the un-vectored Modoc virus in hamster
kidney cells [68],TBEV in non-human primates [69–74] and a
number of Japanese encephalitis serocomplex viruses [75–79].
JEV and WNV have been shown to be capable of establishing
persistent infection of the nervous system in humans and non-
human primates with isolatable virus detected up to 5 K months
after infection [76,78]. Interestingly, WNV appears to have some
specific propensity to establish persistent infection in the kidneys
resulting in virus being shed in the urine [76,77,79]. In fact the
detection of WNV RNA in human urine samples collected up to
6.7 years following primary infection suggests that persistent
infection may result in the chronic symptomology experienced by
some patients [79]. It should be noted that infectious virus has
never been isolated from serum samples in any persistently
infected animals/humans beyond the initial acute viremia (5–7
days post infection). Therefore the epidemiological implications in
terms of the ability to facilitate recombination and natural
arthropod-borne transmission remain unknown.
T h es t u d i e sd e s c r i b e dh e r ew e r er a t i o n a l l yd e s i g n e dt o
provide empirical data to assess the potential for flavivirus
recombination using YFV 17D replicons bearing complemen-
tary in-frame E coding sequence deletions. The constructs were
designed to strongly favor recombination, and the detection
conditions were optimized to achieve high sensitivity recovery of
putative recombinants. Electroporation of these constructs into
BHK-21 cells both with and without a VEEV packaging
construct, capable of supplementing functional envelope in trans,
verified the viability and ‘‘suicide’’ phenotype of these replicons
(data not shown). Interestingly, replicon particle titers harvested
from packaging cells were $1000-fold less than as previously
reported for YFV 17D replicon genomes [56]. Both of the
deletion mutant replicons (17D 59 DE and 17D 39 DE) are
competent for the expression of an E protein that has a large
internal deletion. 17D 59 DE contains an 80aa deletion within E
dimerization domain (DII) including the fusion loop (aa 98–
110), while the majority of the receptor binding domain (89aa of
E DIII) has been removed from 17D 39 DE. However, although
major functional domains have been removed, these replicons
have been designed in such a way that E truncated proteins
should be expressed and maintain the correct transmembrane
topologies of the native 17D E protein. It was possible that these
truncated E proteins may have been incorporated into replicon
containing virus-like-particles. If this were to happen, these
particles would have significantly impaired infectivity due to
their inability to interphase with cellular receptors and/or
initiate fusion of the viral and endosomal membranes.
Furthermore, a second possible explanation for these titer
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may in some way disrupt particle assembly.
McGee et al., (2008) hypothesized that because flaviviral
infection in a mosquito/tick is persistent, in nature recombination
would most likely occur in the arthropod vector [80]. Indeed the
persistent replication in a mosquito vector can be quite long-lived
as Ae. aegypti mosquitoes experimentally infected with Asibi have
been observed to fatally infect monkeys for up to 168 days post-
infectious bloodmeal [81]. Since 17D and 17D chimeric vaccines
exhibit an impaired ability to escape the mosquito midgut,
recombination events occurring between a vaccine and wt
flavivirus would have to occur with co-infected midgut epithelial
cells. The mosquito midgut is estimated to be comprised of ,10
4
epithelial cells [82]. Analysis by Smith et al., (2008) suggest that
only a small sub-population of these cells, perhaps 100, are
susceptible to primary infection with Venezuelan equine enceph-
alitis virus, a conclusion which has been further supported by the
observations of relatively low numbers of primary WNV midgut
infections regardless of input titer [57,83]. Taken together, these
data suggest that, although virus may be capable of spreading cell-
to-cell throughout the entire midgut in an infected individual, for
any given mosquito-borne virus only a small sub-population of
midgut epithelial cells may be susceptible to primary infection,
although the actual population of susceptible cells may be different
for each virus. Thus the levels of co-infection described here,
specifically with regard to arthropod cells (electroporation of C710
with 17D 59 DE-Cherry and 17D 39 DE-GFP RNAs reproducibly
resulted in $10
5 co-infections), are highly significant because they
suggest that even if every cell within the mosquito gut were
simultaneously co-infected with two distinct flaviviruses, a
recombinant virus would still not likely be produced.
Seligman and Gould (2008) recently argued that the predom-
inant risk for flavivirus recombination was in the vertebrate host,
given the potential for wt persistence and adverse vaccine
replication. However, in vivo YFV homologous interference
(superinfection resistance) was noted by Hoskins (1935) who
observed that simultaneous or subsequent (within 48 h) inocula-
tion of Macacus rhesus with YFV viscerotropic (Asibi) and
Figure 5. Superinfection of YFV Asibi GFP infected Vero and C710 cells with either YFV 17D Cherry or CHIKV 59 Cherry. A) YFV 17D-
Cherry growth kinetics on naı ¨ve (%) and YFV Asibi GFP infected (&) Vero monolayers. B) YFV 17D Cherry growth kinetics on naı ¨ve (#) and YFV Asibi
GFP infected (N)C 710 monolayers. C) CHIKV 59 Cherry growth kinetics on naı ¨ve (D) and YFV Asibi GFP infected (m) Vero monolayers. D) CHIKV 59
Cherry growth kinetics on naı ¨ve (e) and YFV Asibi GFP infected (¤)C 710 monolayers. Titers expressed as log10TCID50/mL.
doi:10.1371/journal.pone.0023247.g005
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Asibi [84]. Since no detailed molecular techniques were available
at that time it is difficult to determine if this resulted from
superinfection resistance at the cellular level or via some immune/
interferon mediated mechanism. Nevertheless, these data argue
that if a natural co-infection were to happen during the course of
vaccination uncontrolled dual replication would not likely occur.
Given that vertebrate hosts can facilitate high titer replication of
wt flaviviruses the potential for acute high level co-infection to
facilitate YFV 17D recombination in vertebrate cells was
examined. Co-electroporation of 17D 59 DE-Cherry and 17D 39
DE-GFP RNAs was observed to result in high level co-infection in
BHK-21 ($10
6) cells as indicated by cells positive for the
expression of both GFP and Cherry. Despite this artificially high
level of co-infection at the cellular level and a lower limit of
detection of ,5 infectious units, no recombinant full length YFV
17D was detected. As such, these data strongly argue that even if
acute robust post-vaccination replication were to occur within a
vaccinee, recombination is unlikely. Furthermore given that
recombination is a replication driven mechanism resulting from
a template switching phenomenon of the viral polymerase and all
ChimeriVax
TM vaccine genomes derived their replicative ma-
chinery from the parental YFV 17D genome it is reasonable to
expect similar recombination efficiency, or lack thereof, for these
viruses.
A similarly designed study, described by Taucher et al., (2009),
also failed to detect recombinant tick-borne encephalitis virus
(TBEV) and West Nile virus (WNV). Furthermore, recent analyses
of YFV 17D trans-complementing pseudoinfectious genomes also
failed to detect the generation of any viable recombinant full
length virus despite sustained serial passage [56,85]. It should be
noted, however, that specific sequence manipulations were
engineered into the YFV 17D genomes used by Shustov et al.,
(2007; 2010) to decrease sequence homology specifically with the
goal of prevention of recombination. Although the study by
Taucher et al., (2009), did not result in TBEV or WNV
recombination, it did provide the first experimental evidence of
the generation of viable flavivirus recombinants under extreme
laboratory conditions using a Japanese encephalitis virus (JEV)
replicon/replicon ‘‘recombination trap’’ [39]. In these studies,
persistent high level co-infection, via serial passage in BHK cells,
of trans-complementing JEV genomes was required to yield full
length virus [39]. JEV recombinants isolated from this system were
aberrantly homologous and contained sequence duplications.
Cross-overs were observed to occur within the NS1 gene resulting
in duplications of NS1 and both structural cassettes including their
in-frame structural deletions. Analysis of the attenuated in vitro
growth characteristics of these recombinants as compared to wt
suggested that under a natural co-infection these recombinants
would not be fit for selection relative to the parental viruses.
The lack of recombination of YFV using 17D in our studies as
compared to JEV may be due to differences between the
topologies of our replicons and those used by Taucher and
coworkers. The 17D replicons used for our studies contained
specific internal deletions of E coding sequences, while JEV
replicons described by Taucher et al., (2009) contained major
deletions of different proteins, C and E. Thus, while our system
required recombination to occur within the coding sequence of a
single protein, the JEV system employed by Taucher et al., (2009)
allowed for expression of both truncated and full length C and E
from a single covalently linked genome. Therefore, it is possible
that the efficiency of generating a viable recombinant within the
17D system was less than that using the JEV system. A second
possible explanation is that particular species of mosquito-borne
flaviviruses may simply have different propensities to participate in
recombination, indeed WNV and TBEV systems designed using
similar topologies to the JEV recombinant cross did not generate
viable recombinant virus. Furthermore, it is possible that the
ability for different viruses to undergo recombination and/or for
recombinants to be detected may be highly influenced by the
specific cell culture conditions employed. Interestingly, even given
its apparent propensity to recombine, the generation of JEV
recombinants required three to five passages in cell culture. These
data suggest that the efficiency of flavivirus recombination may be
extremely low and in fact may require long-term sustained or
persistent co-infection to allow for sporadic template switching to
occur. Although such infections are known to occur for
pestiviruses, via an immunotolerance mechanism, they appear to
be unlikely for flaviviruses because of the acute nature of flavivirus
infection in vertebrate hosts. Given the mounting experimental
evidence against homologous recombination of flaviviruses both
vaccine (17D) and wt (WNV, JEV, TBEV) as reported here and by
Taucher and coworkers it is logical to conclude that in general
arthropod-borne flaviviruses do not homologously recombine
under acute co-infection circumstances and those extremely rare
events that generate aberrant genomes are rapidly selected out of
the viral population due to their decreased relative fitness.
Distinct similarities in post-recombination genome topologies
can be observed for CHIKV intra-genic recombinants reported
here and those of JEV recombinants as reported by Taucher et al.,
(2009) (i.e. both contained non-homologous duplications of
truncated structural genes). This supports our ability to extrapolate
between alphavirus and flavivirus systems to draw general
conclusions regarding RNA arbovirus recombination. Flavivirus
recombination, like alphavirus recombination, when examined in
the laboratory, appears to occur by non- homologous or
aberrantly homologous template switching. This is perhaps not
surprising giving that the likelihood of polymerase disassociation
and re-initiation at specific homologous sites would require a high
level of precision and perhaps facilitation by accessory proteins,
none of which have been identified. However, reports of naturally
occurring mosquito-borne flavivirus and alphavirus recombinants
suggest that these viruses may undergo precisely homologous
recombination in nature, with no aberrant sequence duplications,
insertions, or deletions.
A critical analysis of the phylogenetic reports of DENV
recombination suggests that not only is recombination occurring
in nature, but that multiple completely homologous polymerase
jumps are possible, and can result in the generation of mosaic
DENV genomes [31,35–37]. In fact, one report by Chen et al.,
(2008) has identified a DENV 1 genome with three recombinant
regions coincident with six homologous polymerase template
switches.
We propose that the assertion that a flavivirus can undergo
multiple homologous template switches and produce a recombi-
nant progeny that is viable during a single co-infection represents a
completely naı ¨ve view with respect to the nature of the molecular
interactions involved. Working with CHIKV which seems highly
amenable to recombination, or to a significantly disrupted gene
order that allows for a much lower frequency recombination event
to produce viable progeny, we have quantified the rate of intra-
genic recombination to require at least 10
5 co-infected cells to
facilitate a single template switching event. If we were to
extrapolate the conditions required to achieve six polymerase
jumps, even if the nature of those switches (homologous vs. non-
homologous) is disregarded, then ,10
30 co-infections would be
required. Given that the suggested incidence of an adverse
flavivirus vaccine event while simultaneously experiencing a wt
Recombination of Yellow Fever and Chikungunya
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possibility of even a double homologous template switch during
acute replication is highly unlikely.
Although, the molecular interactions that facilitate flavivirus
recombination at the molecular level appear to be extremely
inefficient there must be some finite possibility for such an event to
occur should two functional templates exist in a single cell. In the
recombinant crosses reported here this is achieved via electrical
transfection of both genomes. However, in nature a single cell
must be infected via virion-receptor mediated events with two
viruses either simultaneously or more likely sequentially. As such,
this represents a second potential obstacle to recombination. Intra-
mosquito reports of flavivirus superinfection resistance are scarce.
One report by Sabin (1952) suggests that Ae. aegypti mosquitoes
harboring a primary infection with DENV become resistant to
superinfection with YFV [87]. However, because no data
regarding the number of individual mosquitoes assayed were
provided the extent of this resistance is unclear. In vitro analyses of
DENV co- and superinfection indicate that the suppression of
heterotypic replication can be induced very rapidly, within 20 h
post-primary infection [88,89]. This type of resistance can be
relatively long lived as DENV persistently infected C6/36 cells
have been observed to produce significantly lower titers of a
secondary challenge virus even when infections were separated by
50 days [90]. A recent study of WNV superinfection has begun to
provide some insights into the mechanism of flavivirus superin-
fection resistance [91]. Zou et al., (2009) demonstrated that
replication of WNV was significantly decreased in cells harboring
a persistently WNV replicon infection. Interestingly, this resistance
could be overcome by specific mutations in E and NS4A which
appeared to increase particle-receptor binding interactions and the
affinity for interactions with host factors required for replication.
Therefore, it was suggested that flavivirus superinfection resistance
may result from sequestering of critical host factors by the
replicative complex of the primary virus, which exists in
abundance relative to the secondary virus [91].
To determine if a similar phenomenon could be observed for
YFV, Vero and C710 cells were superinfected with YFV 17D
following primary infection with YFV Asibi. While Asibi infected
C710 cells appear to become completely refractory to 17D
infection/replication superinfected Vero cells appear to be fairly
permissive for 17D replication. It was noted by Zou et al., (2009)
that WNV superinfection resistance could be overcome by
selection for viruses containing mutations which increased
receptor binding affinity and RNA replication kinetics [91].
Indeed YFV 17D is a highly adapted to vertebrate cell culture [92]
and as such may possess some, as of yet, unidentified mutations
which allow for escape from superinfection resistance in vertebrate
cells. The ability of CHIKV to replicate to similar titers and at
similar kinetics in both Vero and C710 cells harboring a primary
infection with YFV Asibi suggest that primary YFV infection does
not induce a non-specific antiviral state in these cell types.
Taken together the observations as reported here and those
published by others[39] have repeatedly demonstrated that: 1) the
safety and efficacy of live attenuated and chimeric live attunated
flavivirus vaccines [43,93] 1) if a recombinant flavivirus does arise
following acute dual infection in a vertebrate host then it would
likely be attenuated and likely be selected against, 2) if an
arthropod vector was to become exposed to two distinct
flaviviruses, the likelihood of sequential co-infection and/or
recombination is extremely remote, and 3) even if what would
be considered ‘‘worst-case’’ post-recombination genome topology
were to occur, vaccine safety would not be compromised [80,94].
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